Design and Analysis of Biosimilar Switching Studies

Area of Science:

• Pharmacoeconomics
• Clinical Trial Design
• Regulatory Science

Background:

• The Biologics Price Competition and Innovation Act (BPCI) facilitates biosimilar development, offering cost-effective alternatives to reference biologics.
• Increasing numbers of available biosimilars raise concerns about their interchangeability and potential impact on treatment outcomes.
• Evaluating the safety and efficacy implications of switching between reference and biosimilar products is critical for clinical practice.

Purpose of the Study:

• To examine the statistical properties, analyses, and sample size requirements of switching study designs for biosimilar interchangeability.
• To compare the efficiency of proposed switching study designs against the complete n-of-1 trial design.
• To inform regulatory approaches for assessing biosimilar interchangeability.

Main Methods:

• Analysis of statistical properties of 2x2 crossover designs (RT, RR) for single switches.
• Evaluation of designs (RTR, RRR) and (RTRT, RRRR) for multiple switches, as suggested by FDA draft guidance.
• Comparative efficiency analysis against complete n-of-1 trial designs.

Main Results:

• Detailed examination of the statistical characteristics of FDA-suggested switching study designs.
• Assessment of sample size needs for evaluating biosimilar interchangeability using these designs.
• Comparative efficiency data highlighting the performance of switching designs versus n-of-1 trials.

Conclusions:

• Switching study designs provide a framework for evaluating biosimilar interchangeability.
• Understanding the statistical properties and efficiencies of these designs is essential for regulatory decision-making.
• These analyses support the development and adoption of safe and effective biosimilar therapies.